Tris[2-(Acryloyloxy)Ethyl]Isocyanurate Cross-Linked PolyethylenimineEnhanced Exon-Skipping of Antisense 2′-Omethyl PhosphorothioateOligonucleotide in vitro and in vivo

@article{Wang2015Tris2AcryloyloxyEthylIsocyanurateCP,
  title={Tris[2-(Acryloyloxy)Ethyl]Isocyanurate Cross-Linked PolyethylenimineEnhanced Exon-Skipping of Antisense 2′-Omethyl PhosphorothioateOligonucleotide in vitro and in vivo},
  author={Mingxing Wang and Bo Wu and Jason D Tucker and Peijuan Lu},
  journal={Journal of Nanomedicine \& Nanotechnology},
  year={2015},
  volume={6},
  pages={1-9}
}
Branched poly(ester amine)s (PEAs) based on tris[2-(acryloyloxy)ethyl]isocyanurate (TAEI) cross-linked low molecular weight polyethylenimine (LPEI, Mw: 0.8k/1.2k/2.0k) polymers have been evaluated for their ability to deliver antisense 2′-O-methyl phosphorothioate RNA (2′-OMePS) through in vitro and in dystrophic mdx mice. Almost all PEAs improved exon-skipping of 2′-OMePS both in vitro and in vivo. Especially the PEAs composed of PEI 2.0k (C series) enhanced 2′-OMePS delivery more effectively… Expand

Figures and Tables from this paper

Poly(ester amine) Composed of Polyethylenimine and Pluronic Enhance Delivery of Antisense Oligonucleotides In Vitro and in Dystrophic mdx Mice
TLDR
PEAs improve PMO delivery more effectively than 2′-OMePS delivery in vivo, and the systemic delivery evaluation further highlight the efficiency of PEA for PMO Delivery in all skeletal muscle. Expand
In Vivo Evaluation of Dystrophin Exon Skipping in mdx Mice.
TLDR
Key considerations and the essential methodologies in detail are described for exon skipping in mdx mice for the development of antisense therapy in vivo. Expand
Treating Duchenne Cardiomyopathy in the Mouse Model by Gene Repair
TLDR
It is suggested that persistent dystrophin expression is essential for continuous muscle and heart protection in early life and not just in adulthood, as previously suggested. Expand

References

SHOWING 1-10 OF 35 REFERENCES
Evaluation of Tris[2-(acryloyloxy)ethyl]isocyanurate cross-linked polyethylenimine as antisense morpholino oligomer delivery vehicle in cell culture and dystrophic mdx mice.
TLDR
Improved transfection efficiency and lower toxicity indicate the potential of the biodegradable PEA polymers as safe and efficient PMO delivery vectors for in vivo applications. Expand
Tris[2-(acryloyloxy)ethyl]isocyanurate cross-linked low-molecular-weight polyethylenimine as gene delivery carriers in cell culture and dystrophic mdx mice.
TLDR
Higher transfection efficiency and lower toxicity indicate the potential of the biodegradable PEAs as safe and efficient transgene delivery vectors. Expand
Pluronic–PEI copolymers enhance exon-skipping of 2′-O-methyl phosphorothioate oligonucleotide in cell culture and dystrophic mdx mice
TLDR
The data demonstrate the potential of PCMs to mediate delivery of modified antisense oligonucleotides to the muscle for treating muscular dystrophy or other appropriate myodegenerative diseases. Expand
Polyethylenimine-modified pluronics (PCMs) improve morpholino oligomer delivery in cell culture and dystrophic mdx mice.
TLDR
Application of optimized formulations of PCMs with PMO targeted to dystrophin exon 23 demonstrated a significant increase in exon-skipping efficiency in dystrophic mdx mice, indicating the potential of the PCMs as effective and safe PMO carriers for treating diseases such as muscular dystrophy. Expand
Efficient gene delivery with osmotically active and hyperbranched poly(ester amine)s.
Degradable and hyperbranched poly (ester amine)s (PEAs) were successfully synthesized by Michael addition reaction between hydrophilic glycerol triacrylate (GTA) and low-molecular-weightExpand
Functionalized PEG-PEI copolymers complexed to exon-skipping oligonucleotides improve dystrophin expression in mdx mice.
TLDR
Data indicate that TAT-modified PEG-PEI copolymers are effective carriers for delivery of ESOs to skeletal muscle and are promising compounds for the therapeutic treatment of DMD. Expand
Preclinical PK and PD Studies on 2′-O-Methyl-phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model
TLDR
The results demonstrate that the levels of oligonucleotides in dystrophin-deficient muscle fibers are much higher than in healthy fibers, leading to higher exon-skipping levels, and this patient-convenient delivery method is selected for future clinical study protocols. Expand
Long-term Exon Skipping Studies With 2′-O-Methyl Phosphorothioate Antisense Oligonucleotides in Dystrophic Mouse Models
TLDR
The results indicate that long-term subcutaneous treatment in dystrophic mouse models with these AONs is safe and beneficial and suggests that the mdx/utrn+/− model may be a more suitable model to test potential therapies than the regular mdx mouse. Expand
Induction of dystrophin expression by exon skipping in mdx mice following intramuscular injection of antisense oligonucleotides complexed with PEG-PEI copolymers.
TLDR
It is concluded that low Mw PEI2000(PEG550) copolymers function as high-capacity, nontoxic AO carriers suitable for in vivo transfection of skeletal muscle and are promising compounds for potential use in molecular therapy of DMD. Expand
Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function
TLDR
Peptide-conjugated AOs have significant potential for systemic correction of the DMD phenotype, with robust sarcolemmal relocalization of the dystrophin-associated protein complex and functional improvement in muscle. Expand
...
1
2
3
4
...